We studied the cell killing effects of cisplatin (CDDP), 3',5'-dichloromethotrexate (DCM), and different combinations of these drugs in a human colon carcinoma line (HCT-8). Using a clonogenic assay, the ED50 values for DCM were 3, 0.3, and 0.05 microM after 4-, 24-, and 48-hour exposure, respectively, while cell kill induced by CDDP was less time-dependent (ED50 values: 16, 7.8, 3.3, and 2.8 microM after 2-hour, 4-hour, 24-hour, and continuous incubation, respectively). Sequential exposure of these cells to DCM followed by CDDP resulted in synergism at every dose studied. The synergy was maximal with short DCM pretreatment intervals and decreased with increasing lengths of exposure to the antifol. In contrast, simple additive effects were observed when DCM was given together with or following CDDP. Considering the significant hepatic inactivation of both these compounds, our in vitro data encourage the design of clinical protocols with the sequence DCM----CDDP for hepatic arterial infusion treatment of liver metastasis from colon cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

human colon
8
colon carcinoma
8
ed50 values
8
dcm cddp
8
dcm
5
sequence-dependent synergism
4
synergism dichloromethotrexate
4
dichloromethotrexate cisplatin
4
cisplatin human
4
carcinoma cell
4

Similar Publications

The potential for mitigating intestinal inflammation through the gut-bone axis in the treatment of osteoporosis is significant. While various gut-derived postbiotics or bacterial metabolites have been created as dietary supplements to prevent or reverse bone loss, their efficacy and safety still need improvement. Herein, a colon-targeted drug delivery system is developed using surface engineering of polyvinyl butyrate nanoparticles by shellac resin to achieve sustained release of postbiotics butyric acid at the colorectal site.

View Article and Find Full Text PDF

we report the case of a recurrent giant pseudopolyp occurring in a patient without a history of inflammatory bowel disease (IBD), with an asymptomatic interval of nine years. Case Presentation: a 51-year-old Caucasian male with no relevant medical history was hospitalized for a subocclusive mass in the right colon, suspected to be neoplastic. He underwent a right hemicolectomy, and the histopathology revealed a giant pseudopolyp without malignancy.

View Article and Find Full Text PDF

tumour specific surgery in colon cancer is gaining popularity among colorectal surgeons. Many advocate adapting surgical technique based on preoperative CT staging as not all patients require complete mesocolic excision (CME) and D3 lymphadenectomy. We aimed to assess the sensitivity and specificity of preoperative CT scans in nodal staging and analyse whether inadequate CT staging could have influenced local recurrences.

View Article and Find Full Text PDF

Aim: To assess recent colonoscopies and CT scans in conjunction with the feacal immunochemical test (FIT) for possibly downgrading urgent suspected cancer (USC) referrals.

Methods:  A retrospective single-centre study was conducted, including all USC referrals for colonoscopy in 2022, excluding anal cancers. The CT and colonoscopy findings for a two-year period prior to the referral, along with the FIT result (if done), were noted.

View Article and Find Full Text PDF

Colonic epithelium is situated above a layer of fibroblasts that provide supportive factors for stem cells at the crypt base and promote differentiation of cells in the upper crypt and luminal surface. To study the fibroblast-epithelial cell interactions, an crypt model was formed on a shaped collagen scaffold with primary epithelial cells growing above a layer of primary colonic fibroblasts. The crypts possessed a basal stem cell niche populated with proliferative cells and a differentiated, nondividing cell zone at the luminal crypt end.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!